ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
우파다시티닙 시장 규모는 최근 급속히 확대되고 있습니다. 2024년 13억 2,000만 달러, 2025년에는 15억 달러에 달하고, CAGR 13.8%로 성장할 전망입니다. 역사적인 기간의 성장은 자가면역 질환의 이환율 증가, 환자 지원 프로그램, 각국의 적극적인 규제 승인 증가, 가처분 소득 증가, 헬스케어 인프라 증가로 인한 것입니다.
우파다시티닙 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 14.1%로 25억 4,000만 달러로 성장할 것으로 예상됩니다. 예측 기간의 성장은 류마티스 관절염의 이환율 증가, 환자 지원 프로그램, 전통적인 DMARDs의 수용률 증가, 류마티스 관절염 증상에 대한 인식을 넓히기 위한 정부의 혁신, 치료에 대한 FDA 승인 증가 등에 기인합니다. 예측 기간의 주요 동향은 표적 치료제와 바이오마커의 채택, 실제 데이터 분석, 가치 기반 케어의 중시, 특이적 JAK 억제제의 개발, 생물학적 제제의 진보를 포함합니다.
우파다시티닙은 야누스 키나아제(JAK) 억제제이며 염증 과정에 관여하는 특정 효소를 표적으로 하여 다양한 염증 증상의 치료에 사용됩니다. 중등도에서 중증의 류마티스 관절염(RA) 및 기타 자가면역질환에 처방되어 기존의 질환 수식성 항류마티스약(DMARDs)이나 생물학적 제제를 대체하는 표적 치료제로서 경구 투여라는 편리성을 부가하고 있습니다.
우파다시티닙의 주요 제품 유형은 야누스 키나아제 억제제, 항류마티스제, 저분자 의약품을 포함합니다. Yanus kinase(JAK) 억제제는 Yanus kinase 효소의 활성을 억제하여 염증을 억제하고자가 면역 질환을 관리합니다. 우파다시티닙은 류마티스 관절염, 건선성 관절염, 크론병 등 다양한 용도로 사용되며, 병원, 재택치료, 전문 클리닉 등 여러 최종 사용자가 이용하고 있습니다.
2025년 봄 미국 관세의 급상승과 이에 따른 무역 마찰은 의료 분야, 특히 필수적인 의료기기, 진단 장비 및 의약품 공급에 큰 영향을 미쳤습니다. 병원과 건강 관리 제공업체는 수입되는 수술 기구, 영상 진단 시스템, 주사기 및 카테터와 같은 소모품의 비용 상승에 시달리고 있으며, 그 대부분은 국내 대체품이 제한되어 있습니다. 이러한 비용 상승이 의료 예산을 압박하기 때문에 일부 의료기관은 장비 업그레이드를 늦추거나 비용 증가를 환자에게 전가하고 있습니다. 게다가 원료와 부품에 대한 관세는 중요한 의약품과 의료기기의 제조에 지장을 주고 공급망의 지연으로 이어지고 있습니다. 이에 비해 업계는 다양한 조달 전략을 채택하고 가능한 한 현지 생산을 확대하고 중요한 의료 제품의 관세 면제를 수행하고 있습니다.
이 조사 보고서는 우파다시티닙 산업 세계 시장 규모, 지역 점유율, 우파다시티닙 시장 점유율을 가진 경쟁업체, 상세한 우파다시티닙 시장 부문, 시장 동향, 비즈니스 기회 등 우파다시티닙 시장 통계를 제공하는 The Business Research Company의 신간 보고서 시리즈 중 하나입니다. 이 우파다시티닙 시장 조사 보고서는 업계의 현재 및 미래 시나리오를 자세히 분석하고 필요한 모든 것에 대한 완전한 전망을 제공합니다.
향후 5년간의 성장률 14.1%라고 하는 예측은 이 시장의 전회 예측으로부터 0.4%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 장벽은 스위스와 아일랜드에서 조달하는 우파다시티닙(JAK 억제제)의 비용을 상승시키고, 관절염 류마티스와 궤양성 대장염의 치료를 지연시키고, 전문 약국의 지출을 증가시킴으로써 미국에 지장을 초래할 것으로 예측됩니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.
자가면역 질환의 이환율 증가는 향후 수년간 우파다시티닙 시장의 성장을 가속할 것으로 예측됩니다. 자가면역질환은 면역체계가 체내의 건강한 세포를 외국 위협으로 오인하고 공격함으로써 발생합니다. 이러한 질병의 발생이 증가하고 있는 것은 유전적 소인, 환경적 유인, 라이프 스타일이나 면역계 기능의 변화가 원인이 되고 있습니다. 우파다시티닙은 JAK1을 선택적으로 억제함으로써 류마티스 관절염 및 건선성 관절염과 같은 질환에서 염증을 억제하고 면역 반응을 조절함으로써 자가면역 질환 관리에 중요한 역할을 합니다. 예를 들어, 2024년 11월 독일에 본사를 둔 헬스케어 데이터 분석 회사인 Versorgungsatlas de는 2022년 630만 4,340명이 적어도 하나의 자가면역 질환으로 진단되었다고 보고하였으며, 이는 생병률 8.61%에 해당합니다. 그 결과 자가면역질환의 유병률 증가가 우파다시티닙 시장 확대에 박차를 가하고 있습니다.
우파다시티닙 시장 진출기업들은 자가면역질환을 관리하는 옵션을 늘리기 위해 경구 야누스키나아제(JAK) 억제제와 같은 혁신적인 치료법의 개발을 선호하고 있습니다. 이러한 경구 억제제는 야누스 키나아제 효소를 억제하는 저분자 약물로 과도한 면역 활성과 염증을 억제하고자가 면역 질환 및 염증성 질환을 효과적으로 치료합니다. 예를 들어, 2023년 4월 미국 제약회사인 아비는 RINVOQ(우파다시티닙)이 중등도에서 중증 활동성 크론병 치료제로 유럽위원회의 승인을 받았다고 발표했습니다. 이 경구제는 1일 1회 투여가 가능하여 환자의 복약 준수와 치료의 편의성을 향상시킵니다. 전통적인 치료제와 비교할 때 경구 투여는 작용 발현이 빠르기 때문에 환자는 치료 요법을 유지하기 쉽습니다.
2022년 11월 인도에 본사를 둔 제약회사인 Caprin Point Laboratories Limited는 Metrochem API Private Limited에서 API 플랜트를 비공개 금액으로 취득했습니다. 이 인수로 Caprin Point Laboratories는 보다 광범위하고 고품질의 API 제품 생산 능력을 강화하고 공급망을 강화하며 규제 시장에서 도달범위를 확대했습니다. 마찬가지로 인도에 본사를 둔 Metrochem API Private Limited는 우파다 시티닙 제조에 종사하는 제약 회사입니다.
우파다시티닙 시장은 면역억제제와 항염증제 판매로 구성되어 있습니다. 이 시장의 가치는 '팩토리게이트' 가치, 즉 상품의 제조자 또는 제작자가 다른 기업(다운스트림 제조업자, 도매업체, 유통업체, 소매업체 포함) 또는 직접 최종 고객에게 판매한 상품의 가치입니다. 이 시장에서 상품의 가치에는 상품 제작자에 의해 판매되는 관련 서비스도 포함됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 우파다시티닙 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 우파다시티닙 시장 : 성장률 분석
세계의 우파다시티닙 시장 실적 : 규모와 성장, 2019-2024
세계의 우파다시티닙 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 우파다시티닙 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 우파다시티닙 시장 : 제품별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
야누스 키나아제 억제제
항류마티스약
저분자 의약품
세계의 우파다시티닙 시장 : 용도별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
류마티스 관절
건선성 관절염
크론병
세계의 우파다시티닙 시장 : 최종 사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
병원
홈케어
전문 클리닉
기타 최종 사용자
세계의 우파다시티닙 시장 : 서브세분화 야누스키나아제 억제제(유형별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
JAK1 억제제
JAK2 억제제
JAK3 억제제
TYK2 억제제
세계의 우파다시티닙 시장 : 서브세분화 항류마티스약(유형별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
질환 수식성 항류마티스약(DMARD)
생물학적 DMARD
종래의 합성 DMARD
세계의 우파다시티닙 시장 : 세분화 저분자 의약품(유형별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
경구 소분자약
국소 소분자약
제7장 지역별/국가별 분석
세계의 우파다시티닙 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
세계의 우파다시티닙 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
우파다시티닙 시장 : 경쟁 구도
우파다시티닙 시장 : 기업 프로파일
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc : 개요, 제품 및 서비스, 전략 및 재무 분석
Eli Lilly and Company : 개요, 제품 및 서비스, 전략 및 재무 분석
Curia Global Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Egis Pharmaceuticals PLC : 개요, 제품 및 서비스, 전략 및 재무 분석
Upadacitinib is a Janus kinase (JAK) inhibitor used to treat various inflammatory conditions by targeting and inhibiting specific enzymes involved in the inflammatory process. It is prescribed for moderate to severe rheumatoid arthritis (RA) and other autoimmune diseases, offering a targeted therapy alternative to traditional disease-modifying anti-rheumatic drugs (DMARDs) and biologics, with the added convenience of oral administration.
The primary product types of upadacitinib include Janus kinase inhibitors, antirheumatic agents, and small molecule drugs. Janus kinase (JAK) inhibitors work by blocking the activity of Janus kinase enzymes to reduce inflammation and manage autoimmune diseases. Upadacitinib is used for various applications, such as rheumatoid arthritis, psoriatic arthritis, and Crohn's disease, and is utilized by multiple end users, including hospitals, home care, specialty clinics, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The upadacitinib market research report is one of a series of new reports from The Business Research Company that provides upadacitinib market statistics, including the upadacitinib industry global market size, regional shares, competitors with the upadacitinib market share, detailed upadacitinib market segments, market trends, and opportunities, and any further data you may need to thrive in the upadacitinib industry. This upadacitinib market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The upadacitinib market size has grown rapidly in recent years. It will grow from $1.32 billion in 2024 to $1.5 billion in 2025 at a compound annual growth rate (CAGR) of 13.8%. The growth in the historic period can be attributed to the rising incidence of autoimmune diseases, programs for patient assistance, the rise in positive regulatory approvals in different nations, the increase in disposable income, and the rise in healthcare infrastructure.
The upadacitinib market size is expected to see rapid growth in the next few years. It will grow to $2.54 billion in 2029 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be attributed to the rise in rheumatoid arthritis incidence, programs for patient assistance, the rise in acceptance of traditional DMARDs, government innovations to spread awareness of rheumatoid arthritis symptoms, and rising FDA approvals for the treatment. Major trends in the forecast period include adoption of targeted therapies and biomarkers, real-world data analysis, emphasis on value-based care, development of specific JAK inhibitors, and growing advancements in biologics.
The forecast of 14.1% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of upadacitinib (JAK inhibitor) sourced from Switzerland and Ireland, thereby delaying treatment for rheumatoid arthritis and ulcerative colitis and elevating specialty pharmacy expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing incidence of autoimmune diseases is expected to drive the growth of the upadacitinib market in the coming years. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells, misidentifying them as foreign threats. The rising occurrence of these diseases is attributed to genetic predisposition, environmental triggers, and shifts in lifestyle and immune system function. Upadacitinib plays a crucial role in managing autoimmune conditions by selectively inhibiting JAK1, thereby reducing inflammation and modulating immune responses in disorders such as rheumatoid arthritis and psoriatic arthritis. For instance, in November 2024, Versorgungsatlas de, a Germany-based healthcare data analytics company, reported that 6,304,340 individuals were diagnosed with at least one autoimmune disease in 2022, corresponding to a raw prevalence rate of 8.61%. As a result, the increasing prevalence of autoimmune diseases is fueling the expansion of the upadacitinib market.
Companies operating in the upadacitinib market are prioritizing the development of innovative treatments, such as oral Janus kinase (JAK) inhibitors, to enhance options for managing autoimmune diseases. These oral inhibitors are small-molecule drugs that block Janus kinase enzymes, suppressing excessive immune activity and inflammation to effectively treat autoimmune and inflammatory conditions. For example, in April 2023, AbbVie Inc., a US-based pharmaceutical company, announced that RINVOQ (upadacitinib) had received European Commission approval for the treatment of moderately to severely active Crohn's disease. This oral formulation enables once-daily administration, improving patient adherence and treatment convenience. Compared to traditional therapies, the oral delivery method provides a faster onset of action, making it easier for patients to maintain their treatment regimens.
In November 2022, Caplin Point Laboratories Limited, an India-based pharmaceutical company, acquired an API plant from Metrochem API Private Limited for an undisclosed amount. This acquisition strengthens Caplin Point Laboratories' capacity to manufacture a wider range of high-quality API products, reinforcing its supply chain and expanding its reach in regulated markets. Metrochem API Private Limited, also based in India, is a pharmaceutical company involved in the production of upadacitinib.
Major players in the upadacitinib market are Merck & Co. Inc., AbbVie Inc, Eli Lilly and Company, Curia Global Inc., Egis Pharmaceuticals PLC, Natco Pharma, Morepen Laboratories, Zhejiang Hengkang Pharmaceutical, Sinoway industrial Co. Ltd., Optimus Pharma, Venkatasai Life Sciences, Shandong Chenghui Shuangda Pharmaceutical Co. Ltd., Jinan Tantu Chemicals Co. Ltd., Shandong Loncom Pharmaceutical Co. Ltd., Lee Pharma, TAPI Technology & API Services, Hebi Xinhe Pharmaceutical, Suzhou PengXu PharmaTech Co. Ltd., Anhui Dexinjia Biopharm Co. Ltd., Sichuan Qingmu Pharmaceutical Co. Ltd., Shandong Boyuan Pharmaceutical.
North America was the largest region in the upadacitinib market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in upadacitinib report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the upadacitinib market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The upadacitinib market consists of sales of immunosuppressants and anti-inflammatory agents. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Upadacitinib Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on upadacitinib market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for upadacitinib ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The upadacitinib market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Product: Janus Kinase Inhibitors; Antirheumatic Agents; Small Molecule Drugs
2) By Application: Rheumatoid Arthritis; Psoriatic Arthritis; Crohn's Disease
3) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Upadacitinib Market Characteristics
3. Upadacitinib Market Trends And Strategies
4. Upadacitinib Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Upadacitinib Growth Analysis And Strategic Analysis Framework
5.1. Global Upadacitinib PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Upadacitinib Market Growth Rate Analysis
5.4. Global Upadacitinib Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Upadacitinib Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Upadacitinib Total Addressable Market (TAM)
6. Upadacitinib Market Segmentation
6.1. Global Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Janus Kinase Inhibitors
Antirheumatic Agents
Small Molecule Drugs
6.2. Global Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Rheumatoid Arthritis
Psoriatic Arthritis
Crohn's Disease
6.3. Global Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Homecare
Specialty Clinics
Other End-Users
6.4. Global Upadacitinib Market, Sub-Segmentation Of Janus Kinase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
JAK1 Inhibitors
JAK2 Inhibitors
JAK3 Inhibitors
TYK2 Inhibitors
6.5. Global Upadacitinib Market, Sub-Segmentation Of Antirheumatic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Disease-Modifying Antirheumatic Drugs (DMARDs)
Biologic DMARDs
Conventional Synthetic DMARDs
6.6. Global Upadacitinib Market, Sub-Segmentation Of Small Molecule Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Small Molecule Drugs
Topical Small Molecule Drugs
7. Upadacitinib Market Regional And Country Analysis
7.1. Global Upadacitinib Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Upadacitinib Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Upadacitinib Market
8.1. Asia-Pacific Upadacitinib Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Upadacitinib Market
9.1. China Upadacitinib Market Overview
9.2. China Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Upadacitinib Market
10.1. India Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Upadacitinib Market
11.1. Japan Upadacitinib Market Overview
11.2. Japan Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Upadacitinib Market
12.1. Australia Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Upadacitinib Market
13.1. Indonesia Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Upadacitinib Market
14.1. South Korea Upadacitinib Market Overview
14.2. South Korea Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Upadacitinib Market
15.1. Western Europe Upadacitinib Market Overview
15.2. Western Europe Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Upadacitinib Market
16.1. UK Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Upadacitinib Market
17.1. Germany Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Upadacitinib Market
18.1. France Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Upadacitinib Market
19.1. Italy Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Upadacitinib Market
20.1. Spain Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Upadacitinib Market
21.1. Eastern Europe Upadacitinib Market Overview
21.2. Eastern Europe Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Upadacitinib Market
22.1. Russia Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Upadacitinib Market
23.1. North America Upadacitinib Market Overview
23.2. North America Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Upadacitinib Market
24.1. USA Upadacitinib Market Overview
24.2. USA Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Upadacitinib Market
25.1. Canada Upadacitinib Market Overview
25.2. Canada Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Upadacitinib Market
26.1. South America Upadacitinib Market Overview
26.2. South America Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Upadacitinib Market
27.1. Brazil Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Upadacitinib Market
28.1. Middle East Upadacitinib Market Overview
28.2. Middle East Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Upadacitinib Market
29.1. Africa Upadacitinib Market Overview
29.2. Africa Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Upadacitinib Market Competitive Landscape And Company Profiles
30.1. Upadacitinib Market Competitive Landscape
30.2. Upadacitinib Market Company Profiles
30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. AbbVie Inc Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Curia Global Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Egis Pharmaceuticals PLC Overview, Products and Services, Strategy and Financial Analysis
31. Upadacitinib Market Other Major And Innovative Companies
